Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Laboratory of Diagnosis and Therapy of Lysosomal Disorders, |
RCV000677578 | SCV000803094 | likely pathogenic | Mucopolysaccharidosis type 6 | 2018-01-01 | criteria provided, single submitter | curation | In vitro functional studies supportive of a damaging effect on the gene product (low to no ARSB activity in homozygotes; PS3); Absent from GnomAD (PM2) |
Labcorp Genetics |
RCV000677578 | SCV001235859 | pathogenic | Mucopolysaccharidosis type 6 | 2020-01-15 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. This variant has been reported to affect ARSB protein function (PMID: 8116615). This variant has been observed in individual(s) with mucopolysaccharidosis VI (PMID: 17458871, 8116615, 24107440). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 559798). This variant is not present in population databases (ExAC no frequency). This sequence change replaces cysteine with arginine at codon 192 of the ARSB protein (p.Cys192Arg). The cysteine residue is highly conserved and there is a large physicochemical difference between cysteine and arginine. |
Natera, |
RCV000677578 | SCV002084978 | pathogenic | Mucopolysaccharidosis type 6 | 2020-08-06 | no assertion criteria provided | clinical testing |